RSA 키 (2048)

-----BEGIN PRIVATE KEY----- MIIEvgIBADANBgkqhkiG9w0BAQEFAASCBKgwggSkAgEAAoIBAQC+9wbf/KHqvHQ+ rEue2ex8iOMHZiFV48JEl6JMg7wkt8ugAORU/50rUCzKCkFVAFaraveGhkkePYj4 tbzhle06PEVZyZbHq6RUTBnGIBPNj0KgfGGEWBmmJNbTFTiXXUshzDTXtQV4+c+O djfngH66UCFxTGwBLxIv52PyzQfxk+/fCzR0S1gJ2qKVqpom6HU/SHb9QO8eojNO R2FX6yP/ItZnj3Z33WnRyaTJvdFt/CAJp/lo9WxHCiOzIeNVm2iPW6xHn1FSsqOj 3KO51yvlgzDDSQ2A+MX3QG0j+R+UqLIcTUMicT0IMYvkkeYcl5B+IBrvV+jS7jla xUbgolDfAgMBAAECggEATVSlcRDR1MfJ3xNQcBxZmrioDvf5qdlYcwRgkdGK3+eZ yspxrEXytHZ8HLj4ad6AOlxPric09sz+aZDW0xcugLWlc82hhGvqWMSUb1nQCx7n YSvdJYWzpUcnw0TFrO33ndEe2PcSJ0IqHcubqeCr8PDACixjVDtmhwWRwOHsRJPr WEfC13g9b0URkyEH6N5s7dKnlrgAO9LHhTJjadZ4komxgw/R1OOmLZZYHiQhun1U bMzcDhZ0MAj8gRHzDkBLqKR4X+eRlKlDPkLmus9NzY4JT/9GvlX8r+84EszJanY5 WvmQ+Pt7qU5DAqIyK67jCDFNa/Ik4Mqfc8J7nU3PKQKBgQDq+sVxmpaq8hoXdMSI jQWmuVU6jgJcFbIvitD5MhjSnpIjw1qFOqhwqESMz0nscrJKK9oa/HJtCMIBE1LB 0CPGlu7RAwuOtKpmecNZx1Navz3bTQCFmvNgtBog0DdrArkDH+zXhFN4160GrdLQ p/Nzo4i3NMwPlssMItgd3ZkubQKBgQDQDEip2GSiD/GJtWfMxFXoK4fmJ88LsOgI s92TlRJzjbTwI2D84oS/Hmv33IwRrQ6tHCxzd6/NB7sfRse2OZZKBGKfKyaAvcd+ oz5oToAlQYNhHUM/S6L0wABDYBX46S4HUGLQKgUkolL0ipu7gZN3VZOy5Ht//6uZ qDpV76l8+wKBgQC7S/PBX6Uk0SE2/R4CcdXFVQi4SaVb3PdQqed0GhhrGXYHB5nJ hD3qvlUVn8yeqbWvJVEOHZbfjhGFZe+bCNrbWkc1VqYJs7v3PqsVjqnENZeKi9AU rrO7qxMAgLcLlvn9oZ7ZEmKuecsy/a6CHr0QuZMp5O2ap2llXQjClXWZ6QKBgQDO GU0mjIrsjPTPYdkJXfpofC8tjoQqZb8HV/+KAyR7OodjWPjsrA2rMxzsNxy/Kfwe +4kBfjC24RC7JCgV2iiK/JsiaOHEqbxmNJtPQ2zo+2SGITIMEwbEhSv9ksNRiNYj QrwQ0X+00eVyAZnS/8MxdaJSlsvNel7pYmEf3sK9XwKBgAW1aKQ1o8FHBo5fj0L9 w0j38aObiGZMrUTZKEr9Oc0SEmQQ7xnR/Wj7kF3x/3PmsQZpjdP2Ni+ZnQmizlTX +hJM9GGunC5EpqaPYsuP03np2lz4/7iH6a6BIfQp2+D7S/KYgW1sBiCQIS9ZgByY sjCm4CZYmg9hqSoVwR/C4Uuy -----END PRIVATE KEY-----


-----BEGIN PUBLIC KEY----- MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEAvvcG3/yh6rx0PqxLntns fIjjB2YhVePCRJeiTIO8JLfLoADkVP+dK1AsygpBVQBWq2r3hoZJHj2I+LW84ZXt OjxFWcmWx6ukVEwZxiATzY9CoHxhhFgZpiTW0xU4l11LIcw017UFePnPjnY354B+ ulAhcUxsAS8SL+dj8s0H8ZPv3ws0dEtYCdqilaqaJuh1P0h2/UDvHqIzTkdhV+sj /yLWZ492d91p0cmkyb3RbfwgCaf5aPVsRwojsyHjVZtoj1usR59RUrKjo9yjudcr 5YMww0kNgPjF90BtI/kflKiyHE1DInE9CDGL5JHmHJeQfiAa71fo0u45WsVG4KJQ 3wIDAQAB -----END PUBLIC KEY-----

자유게시판

CS Center

tel. 02-715-4734

am 10:00 ~ pm 6:00

공휴일 휴관
(사전예약 후 관람가능)

010-5217-9505
orbgallery@naver.com

The Background of Flibanserin: From Development to FDA Authorization

페이지 정보

profile_image
작성자 Claude
댓글 0건 조회 21회 작성일 24-04-07 23:12

본문

2 years later on, in 2015, alldaychemist.com the FDA ultimately granted authorization for Flibanserin, noting it as the very first drug accepted to deal with HSDD in premenopausal females. Because its authorization, globalcargo.com.pk Flibanserin has been a game-changer for ladies's health, specifically in the location of sex-related health and wellness. While Flibanserin may not have started as a medicine planned to treat HSDD, its journey and eventual FDA approval have actually had a significant effect on ladies's health.


Instead of treating anxiety, the business determined to explore Flibanserin's possible to take on HSDD. Flibanserin first looked for authorization from the FDA in 2010. Two years later, in 2015, the FDA lastly granted authorization for Flibanserin, marking it as the very first medicine approved to treat HSDD in premenopausal females. Because its approval, Flibanserin has been a game-changer for females's health, particularly in the area of sexual health. While Flibanserin might not have started as a medication meant to deal with HSDD, its trip and ultimate FDA approval have had a substantial impact on females's health.

댓글목록

등록된 댓글이 없습니다.